Introduction
Esophageal cancer remains a worldwide health problem, as it is the fourth most common cause of cancer deaths. 1 Surgery constitutes the backbone of treatment for resectable disease; however, for patients with unresectable disease or contraindication to esophagectomy, chemoradiation therapy (CRT) is the mainstay of treatment. 1 Although improved prognosis has been achieved in patients treated with CRT, side effects caused by chemoradiation including bone marrow suppression, esophagitis, pericarditis, and pneumonia should also be considered in the clinical setting. 2 As a result, it is increasingly important to predict the response to CRT in order to identify patients who can benefit best from CRT while avoiding unnecessary adverse events.
Published studies have demonstrated that clinical and histopathological factors, as well as biomarkers and functional imaging could predict the response to CRT. Functional magnetic resonance imaging (MRI) can be used to detect alterations in tumor pathophysiology. Different tissues have unique diffusion characteristics, as revealed by the apparent diffusion coefficient (ADC), which can be determined from the diffusion-weighted imaging (DWI) measurements. Several studies have investigated the role of ADC in predicting the response to CRT and survival in patients with esophageal cancer. 2, 3 However, the validation of the prognostic role of ADC in a cohort in Chinese patients is lacking. Therefore, we retrospectively analyzed the efficacy of ADC in predicting the response to CRT and survival in patients in our institute.
Materials and methods Patients
Seventy-three patients (54 men, 19 women; median age 63, range , interquartile range [12.5] ) with esophageal squamous cell carcinoma (ESCC) admitted to our center from January 2011 to 2015 were included into this study. All patients had an upper endoscopic examination with tumor biopsy, barium esophagography, and chest and abdominal computed tomography (CT) scans to determine their clinical stages. In seventy-three patients, eight patients were treated with radiotherapy alone, and the remaining patients were treated with chemoradiation. None of the patients underwent surgery before or after chemoradiation. There was one patient in stage 1, four in stage 2, 30 in stage 3, and 38 in stage 4. Written informed consent was obtained from all the patients according to the Declaration of Helsinki and the study was approved by the review boards of the first affiliated hospital of Nanjing Medical University.
chemoradiation
Gross tumor volume (GTV) was delineated by using available resources, including diagnostic CT, barium esophagography, and endoscopic reports. It was defined as visible primary tumor and involved lymph nodes (minor diameter .1 cm on CT scan). Clinical target volume was defined as GTV of primary tumor plus a 3 cm margin craniocaudally with 0.5-0.8 cm lateral margins and GTV of involved nodes. Planning target volume (PTV) was GTV plus a uniform 0.3 cm expanded margin. The prescription dose to cover 95% of PTV was 50 Gy. The dose delivered to the primary tumor site and involved lymph node was increased to 60 Gy (2Gy/ fraction, five fractions/week). Concurrent chemotherapy was used as follows: liposomal paclitaxel 35 mg/m 2 plus cisplatin 25 mg/m 2 was administered on day 1 weekly, for 6 weeks.
Mri protocols
Examination was performed with a 3.0-T MR scanner (Verio Tim; Siemens, Erlangen, Germany) and a 16-channel torso coil. 
region of interest placement
Measurements were obtained on the ADC maps that were reconstructed by using the b-value of 0 and 800 sec/mm². The tumor tissue is characterized by high-signal intensity on DWI and low-signal intensity on ADC maps ( Figure 1 
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Results
The median ADC value of the esophageal cancer tissue was 1.256*10 -3 mm 2 /sec (range: 0.657-2.354*10 -3 mm 2 /sec, interquartile range 0.606*10 -3 mm 2 /sec). The ADC value of cancer of the lower esophagus was significantly higher than that of cancer of the middle esophagus or cancer of the upper esophagus (P=0.0062, Table 1 ). No association was found between ADC value and other clinical variables ( Table 1) . The ADC of patients who have complete response (CR) to chemoradiation was not significantly different from that of patients who did not achieve CR (Table 1) .
survival analysis
While using univariate analysis, we found that presence of lymph node metastasis was significantly associated with a worse survival (P=0.014, hazard ratio [HR] 2.826). There was a trend that patients with T4 diseases had a worse prognosis than those with T1-3 diseases (P=0.081), although this difference was not statistically significant. The median survival of the patients who achieved CR was significantly higher than that of patients who did not (P,0.0001, HR =45.7). The survival of cancer of the middle esophagus was worse than that of those from other sites (13.9 months vs undefined), although the difference is not statistically significant (P=0.0537). We determined if ADC was prognostic in our cohort. According to the previous study, we used 1.1*10 -3 mm 2 /sec as the cutoff of ADC; however, the survival between patients with ADC ,1.1*10 -3 mm 2 /sec and patients with ADC $1.1*10 -3 mm 2 /sec was not significantly different (P=0.1517). We use X-tile to find a cutoff of ADC to best predict the prognosis of these patients. 4 Using 1.076 as the cutoff value of ADC, we divided our patients into two groups, we found that the overall survival of patients with ADC ,1.076*10 -3 mm 2 /sec was significantly worse than patients with ADC $1.076*10 -3 mm 2 /sec (12.9 months vs undefined, P=0.0108, Figure 2 ). We then determined whether ADC was an independent factor that was predictive of survival. We included age, sex, tumor depth, lymph node metastasis, and ADC into multivariate Cox analysis. In multivariate analysis, ADC ,1.076*10 -3 mm 2 /sec was an independent predictor of worse survival in our cohort ( 
Discussion
The diagnostic performance of DWI was first investigated in ESCC. 5 The study by Sakurada et al found that DWI only has a limited role in detecting esophageal cancer or lymph node metastasis. 5 Several studies have established the prognostic value of ADC in ESCC. The study by Aoyaqi et al first demonstrated that the ADC value was useful in predicting treatment response as well as survival for patients with ESCC receiving chemoradiotherapy. 2 Furthermore, the ADC change after treatment was also proven to be a useful marker for evaluating therapeutic responses in several types of cancer. 6 The study by Priola et al demonstrated that, in patients with thymoma, patients with higher ADC have a significantly higher diseasefree survival than patients with lower ADC. 7 In a cohort of 41 patients with head and neck squamous cell carcinoma treated with radiotherapy, ADC calculated with different b-values significantly correlated with disease-free survival or overall survival. 8 Furthermore, in patients with resectable gastric cancer, lower ADC was significantly associated with a negative prognosis. 9 In our study, the range of ADC was 0.657-2.354. The range of ADC values of this cohort was larger than that of the study by Aoyagi et al (range: 0.36-1.86). 2 The range of ADC values of our cohort was also larger than that of the study by Kwee et al, although the exact maximum and minimum value was not documented. 10 The range was similar to that of the study by Giganti et al. 3 The variations of ADC values in these studies could be due to different instruments, different software or different b-values used. We found that low ADC value predicted poor survival in patients with ESCC. However, we have not confirmed the association between ADC value and therapeutic response, probably due to the high CR rate in our cohort. We also found that the ADC value of cancer of the lower esophagus was significantly higher than that of cancer of the middle esophagus or cancer of the upper esophagus, a novel finding that was not previously reported.
The ADC value indicates the diffusion of water in tissues. Several factors, including hypoxia, inflammation, cell density and cell membrane integrity, can affect the diffusion of water in tissues. 11 Previous studies indicated that ADC values inversely correlate with cell density in several malignancies. 12 As a result, low ADC may reflect the aggressiveness of the tumor. 3 And in ESCC, the ADC values decreased with stromal collagen growth; also, a negative correlation was noted between the ADC of tumors and the level of VEGF in tumor tissues, suggesting that low ADC was associated with increased angiogenesis. 13 In patients with esophageal 
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The aDc value in patients with escc carcinoma, elevated angiogenic-factor expression was found to be associated with inferior treatment response and adverse outcome. 14 Combination of earlier studies may partly explain the observation that low ADC value predicted worse outcome in patients with ESCC. 13, 14 However, low ADC value does not always predict worse outcome in other types of cancer. For instance, in patients with nasopharyngeal carcinoma, high pretreatment ADC predicted poor local relapse-free survival and disease-free survival. 15 And Zhang et al found that nasopharyngeal carcinoma patients with low pretreatment ADC responded better to neoadjuvant chemotherapy. 16 These might be due to different pathophysiologies in different types of cancer. As a result, the prognostic value of ADC should be interpreted depending on different types of cancer.
However, our study has several limitations. First, the cohort of this study is relatively small, and it may have caused nonsignificance of some results. Second, we used perfusion-sensitive ADC values, because we included b-values of 0 mm/sec 2 in ADC maps without suppression of tissue perfusion. [17] [18] [19] [20] Thus, the ADC values in our study may be overestimated. Third, although we excluded macroscopic vessels from ROI positioning, microscopic vessels and capillaries may have been included in ROI freehand area of measurement.
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Conclusion
In conclusion, our study confirmed ADC as a prognostic factor in ESCC patients who received chemoradiation. Our results suggest MRI examination using DWI measurements should be performed before the treatment of ESCC patients.
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